Share on StockTwits

Heron Therapeutics (NASDAQ:HRTX) CEO Barry D. Quart purchased 10,000 shares of the stock in a transaction dated Wednesday, June 25th. The shares were purchased at an average cost of $11.75 per share, for a total transaction of $117,500.00. Following the transaction, the chief executive officer now directly owns 61,855 shares of the company’s stock, valued at approximately $726,796. The purchase was disclosed in a filing with the SEC, which is available at this link.

Heron Therapeutics (NASDAQ:HRTX) traded up 2.06% during mid-day trading on Thursday, hitting $11.88. 229,335 shares of the company’s stock traded hands. Heron Therapeutics has a 52-week low of $0.44 and a 52-week high of $15.82. The stock’s 50-day moving average is $11.47 and its 200-day moving average is $11.80.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.07. On average, analysts predict that Heron Therapeutics will post $-3.38 earnings per share for the current fiscal year.

Separately, analysts at Jefferies Group cut their price target on shares of Heron Therapeutics from $20.00 to $18.00 in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $17.43.

Heron Therapeutics Inc, formerly A.P. Pharma, Inc is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.